These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Identification of potential inhibitors for mycobacterial uridine diphosphogalactofuranose-galactopyranose mutase enzyme: A novel drug target through in silico approach. Nayak T; Jena L; Waghmare P; Harinath BC Int J Mycobacteriol; 2018; 7(1):61-68. PubMed ID: 29516888 [TBL] [Abstract][Full Text] [Related]
3. Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches. Dash S; Rathi E; Kumar A; Chawla K; Kini SG Sci Rep; 2024 May; 14(1):11315. PubMed ID: 38760437 [TBL] [Abstract][Full Text] [Related]
4. Development of a coupled spectrophotometric assay for GlfT2, a bifunctional mycobacterial galactofuranosyltransferase. Rose NL; Zheng RB; Pearcey J; Zhou R; Completo GC; Lowary TL Carbohydr Res; 2008 Aug; 343(12):2130-9. PubMed ID: 18423586 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, docking study and biological evaluation of ᴅ-fructofuranosyl and ᴅ-tagatofuranosyl sulfones as potential inhibitors of the mycobacterial galactan synthesis targeting the galactofuranosyltransferase GlfT2. Baráth M; Jakubčinová J; Konyariková Z; Kozmon S; Mikušová K; Bella M Beilstein J Org Chem; 2020; 16():1853-1862. PubMed ID: 32802202 [TBL] [Abstract][Full Text] [Related]
6. Design of novel quinoline-aminopiperidine derivatives as Wang J; Zhao C; Tu J; Yang H; Zhang X; Lv W; Zhai H J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186 [TBL] [Abstract][Full Text] [Related]
7. 1-C-phosphonomethyl- and 1-C-difluorophosphonomethyl-1,4-imino-l-arabinitols as Galf transferase inhibitors: A comparison. Cocaud C; Zheng RB; Lowary TL; Poisson T; Pannecoucke X; Nicolas C; Martin OR Carbohydr Res; 2018 May; 461():45-50. PubMed ID: 29579477 [TBL] [Abstract][Full Text] [Related]
8. Chemical Insight into the Mechanism and Specificity of GlfT2, a Bifunctional Galactofuranosyltransferase from Mycobacteria. Poulin MB; Lowary TL J Org Chem; 2016 Sep; 81(18):8123-30. PubMed ID: 27557056 [TBL] [Abstract][Full Text] [Related]
9. Selectfluor and NFSI exo-glycal fluorination strategies applied to the enhancement of the binding affinity of galactofuranosyltransferase GlfT2 inhibitors. Dumitrescu L; Eppe G; Tikad A; Pan W; El Bkassiny S; Gurcha SS; Ardá A; Jiménez-Barbero J; Besra GS; Vincent SP Chemistry; 2014 Nov; 20(46):15208-15. PubMed ID: 25251918 [TBL] [Abstract][Full Text] [Related]
11. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
12. Tetrameric structure of the GlfT2 galactofuranosyltransferase reveals a scaffold for the assembly of mycobacterial Arabinogalactan. Wheatley RW; Zheng RB; Richards MR; Lowary TL; Ng KK J Biol Chem; 2012 Aug; 287(33):28132-43. PubMed ID: 22707726 [TBL] [Abstract][Full Text] [Related]
13. STD-NMR studies suggest that two acceptor substrates for GlfT2, a bifunctional galactofuranosyltransferase required for the biosynthesis of Mycobacterium tuberculosis arabinogalactan, compete for the same binding site. Szczepina MG; Zheng RB; Completo GC; Lowary TL; Pinto BM Chembiochem; 2009 Aug; 10(12):2052-9. PubMed ID: 19575371 [TBL] [Abstract][Full Text] [Related]
14. STD-NMR studies of two acceptor substrates of GlfT2, a galactofuranosyltransferase from Mycobacterium tuberculosis: epitope mapping studies. Szczepina MG; Zheng RB; Completo GC; Lowary TL; Pinto BM Bioorg Med Chem; 2010 Jul; 18(14):5123-8. PubMed ID: 20591680 [TBL] [Abstract][Full Text] [Related]
15. How Mycobacterium tuberculosis Galactofuranosyl Transferase 2 (GlfT2) Generates Alternating β-(1-6) and β-(1-5) Linkages: A QM/MM Molecular Dynamics Study of the Chemical Steps. Janoš P; Kozmon S; Tvaroška I; Koča J Chemistry; 2018 May; 24(27):7051-7059. PubMed ID: 29575294 [TBL] [Abstract][Full Text] [Related]
16. Anti-tubercular Modelling via QSAR Approach, In Silico Design and Virtual Docking Screening of Designed Hypothetical Inhibitors Against DNA gyrase Protein. Adeniji SE Curr Comput Aided Drug Des; 2021; 17(6):739-758. PubMed ID: 32586260 [TBL] [Abstract][Full Text] [Related]
17. Design of novel isoxazole derivatives as tubulin inhibitors using computer-aided techniques: QSAR modeling, Moukhliss Y; Koubi Y; Zafar I; Alaqarbeh M; Maghat H; Sbai A; Lakhlifi T; Bouachrine M J Biomol Struct Dyn; 2024 Feb; ():1-12. PubMed ID: 38353497 [TBL] [Abstract][Full Text] [Related]
18. In silico repurposing of a Novobiocin derivative for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (Rv2421c). Cloete R; Shahbaaz M; Grobbelaar M; Sampson SL; Christoffels A PLoS One; 2021; 16(11):e0259348. PubMed ID: 34727137 [TBL] [Abstract][Full Text] [Related]
20. In silico discovery and in vitro activity of inhibitors against Billones JB; Carrillo MC; Organo VG; Sy JB; Clavio NA; Macalino SJ; Emnacen IA; Lee AP; Ko PK; Concepcion GP Drug Des Devel Ther; 2017; 11():563-574. PubMed ID: 28280303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]